• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

TLR9 在 MAFLD 和 NASH 中的作用:炎症与代谢的交汇点。

TLR9 in MAFLD and NASH: At the Intersection of Inflammation and Metabolism.

机构信息

Avogadro Development Corp, New York, NY, United States.

出版信息

Front Endocrinol (Lausanne). 2021 Jan 29;11:613639. doi: 10.3389/fendo.2020.613639. eCollection 2020.

DOI:10.3389/fendo.2020.613639
PMID:33584545
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7880160/
Abstract

Toll-Like Receptor 9 (TLR9) is an ancient receptor integral to the primordial functions of inflammation and metabolism. TLR9 functions to regulate homeostasis in a healthy system under acute stress. The literature supports that overactivation of TLR9 under the chronic stress of obesity is a critical driver of the pathogenesis of NASH and NASH-associated fibrosis. Research has focused on the core contributions of the parenchymal and non-parenchymal cells in the liver, adipose, and gut compartments. TLR9 is activated by endogenous circulating mitochondrial DNA (mtDNA). Chronically elevated circulating levels of mtDNA, caused by the stress of overnutrition, are observed in obesity, metabolic dysfunction-associated fatty liver disease (MAFLD), and NASH. Clinical evidence is supportive of TLR9 overactivation as a driver of disease. The role of TLR9 in metabolism and energy regulation may have an underappreciated contribution in the pathogenesis of NASH. Antagonism of TLR9 in NASH and NASH-associated fibrosis could be an effective therapeutic strategy to target both the inflammatory and metabolic components of such a complex disease.

摘要

Toll 样受体 9(TLR9)是一种古老的受体,是炎症和代谢的原始功能所必需的。TLR9 的功能是在急性应激下调节健康系统的内稳态。文献支持肥胖症慢性应激下 TLR9 的过度激活是 NASH 和 NASH 相关纤维化发病机制的关键驱动因素。研究集中在肝脏、脂肪组织和肠道隔室中实质细胞和非实质细胞的核心贡献上。TLR9 被内源性循环线粒体 DNA(mtDNA)激活。肥胖症、代谢功能障碍相关脂肪性肝病(MAFLD)和 NASH 中观察到,由营养过剩引起的慢性升高的循环 mtDNA 水平会导致 TLR9 持续激活。临床证据支持 TLR9 过度激活是疾病的驱动因素。TLR9 在代谢和能量调节中的作用可能在 NASH 的发病机制中具有被低估的贡献。在 NASH 和 NASH 相关纤维化中拮抗 TLR9 可能是针对这种复杂疾病的炎症和代谢成分的有效治疗策略。

相似文献

1
TLR9 in MAFLD and NASH: At the Intersection of Inflammation and Metabolism.TLR9 在 MAFLD 和 NASH 中的作用:炎症与代谢的交汇点。
Front Endocrinol (Lausanne). 2021 Jan 29;11:613639. doi: 10.3389/fendo.2020.613639. eCollection 2020.
2
Hepatocyte mitochondrial DNA drives nonalcoholic steatohepatitis by activation of TLR9.肝细胞线粒体DNA通过激活TLR9驱动非酒精性脂肪性肝炎。
J Clin Invest. 2016 Mar 1;126(3):859-64. doi: 10.1172/JCI83885. Epub 2016 Jan 25.
3
TLR9 is up-regulated in human and murine NASH: pivotal role in inflammatory recruitment and cell survival.Toll样受体9(TLR9)在人类和小鼠非酒精性脂肪性肝炎(NASH)中表达上调:在炎症细胞募集和细胞存活中起关键作用。
Clin Sci (Lond). 2017 Jul 24;131(16):2145-2159. doi: 10.1042/CS20160838. Print 2017 Aug 15.
4
Pathogenesis of NASH: How Metabolic Complications of Overnutrition Favour Lipotoxicity and Pro-Inflammatory Fatty Liver Disease.非酒精性脂肪性肝炎的发病机制:营养过剩的代谢并发症如何导致脂毒性和促炎脂肪性肝病。
Adv Exp Med Biol. 2018;1061:19-44. doi: 10.1007/978-981-10-8684-7_3.
5
The effects of metabolic status on non-alcoholic fatty liver disease-related outcomes, beyond the presence of obesity.代谢状态对非酒精性脂肪性肝病相关结局的影响,超出了肥胖的存在。
Aliment Pharmacol Ther. 2018 Dec;48(11-12):1260-1270. doi: 10.1111/apt.15015. Epub 2018 Oct 23.
6
FGF21: An Emerging Therapeutic Target for Non-Alcoholic Steatohepatitis and Related Metabolic Diseases.成纤维细胞生长因子21:非酒精性脂肪性肝炎及相关代谢性疾病的新兴治疗靶点
Front Endocrinol (Lausanne). 2020 Dec 14;11:601290. doi: 10.3389/fendo.2020.601290. eCollection 2020.
7
Hepatic mitochondrial DNA/Toll-like receptor 9/MicroRNA-223 forms a negative feedback loop to limit neutrophil overactivation and acetaminophen hepatotoxicity in mice.肝脏线粒体DNA/ Toll样受体9/微小RNA-223形成负反馈回路,以限制小鼠中性粒细胞的过度激活和对乙酰氨基酚肝毒性。
Hepatology. 2017 Jul;66(1):220-234. doi: 10.1002/hep.29153. Epub 2017 May 22.
8
NASH: NASH and TLR9.非酒精性脂肪性肝炎:非酒精性脂肪性肝炎与Toll样受体9
Nat Rev Gastroenterol Hepatol. 2016 Mar;13(3):124. doi: 10.1038/nrgastro.2016.20. Epub 2016 Feb 10.
9
Mitochondrial DNA from hepatocytes as a ligand for TLR9: Drivers of nonalcoholic steatohepatitis?来自肝细胞的线粒体DNA作为Toll样受体9的配体:非酒精性脂肪性肝炎的驱动因素?
World J Gastroenterol. 2016 Aug 21;22(31):6965-71. doi: 10.3748/wjg.v22.i31.6965.
10
Role of Myeloid Cell-Specific TLR9 in Mitochondrial DNA-Induced Lung Inflammation in Mice.髓系细胞特异性 TLR9 在小鼠线粒体 DNA 诱导的肺部炎症中的作用。
Int J Mol Sci. 2023 Jan 4;24(2):939. doi: 10.3390/ijms24020939.

引用本文的文献

1
MAFLD: A Comprehensive Review of the Link Between Metabolic Dysfunction and Cardiovascular Risk.MAFLD:代谢功能障碍与心血管风险之间联系的全面综述
Hepat Med. 2025 Aug 19;17:75-90. doi: 10.2147/HMER.S506402. eCollection 2025.
2
Unraveling the Metabolic Pathways Between Metabolic-Associated Fatty Liver Disease (MAFLD) and Sarcopenia.解析代谢相关脂肪性肝病(MAFLD)与肌肉减少症之间的代谢途径
Int J Mol Sci. 2025 May 14;26(10):4673. doi: 10.3390/ijms26104673.
3
From Childhood Obesity to Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Hyperlipidemia Through Oxidative Stress During Childhood.

本文引用的文献

1
A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.一项安慰剂对照试验评估皮下司美格鲁肽在非酒精性脂肪性肝炎中的疗效。
N Engl J Med. 2021 Mar 25;384(12):1113-1124. doi: 10.1056/NEJMoa2028395. Epub 2020 Nov 13.
2
Association of Sarcopenia and NAFLD: An Overview.肌肉减少症与非酒精性脂肪性肝病的关联:综述
Clin Liver Dis (Hoboken). 2020 Sep 4;16(2):73-76. doi: 10.1002/cld.900. eCollection 2020 Aug.
3
The impact of cell maturation and tissue microenvironments on the expression of endosomal Toll-like receptors in monocytes and macrophages.
从儿童肥胖到儿童期氧化应激导致的代谢功能障碍相关脂肪性肝病(MASLD)和高脂血症。
Metabolites. 2025 Apr 24;15(5):287. doi: 10.3390/metabo15050287.
4
Preliminary study on the participation of TLR9 on erythrocyte surface combined with mtDNA in the monitoring of infectious diseases.红细胞表面TLR9与线粒体DNA结合参与传染病监测的初步研究
Front Med (Lausanne). 2025 Feb 19;11:1498627. doi: 10.3389/fmed.2024.1498627. eCollection 2024.
5
Inflammatory Indices and MAFLD Prevalence in Hypertensive Patients: A Large-Scale Cross-Sectional Analysis from China.高血压患者的炎症指标与MAFLD患病率:来自中国的大规模横断面分析
J Inflamm Res. 2025 Feb 4;18:1623-1638. doi: 10.2147/JIR.S503648. eCollection 2025.
6
The accumulation of harmful genes within the ROH hotspot regions of the Tibetan sheep genome does not lead to genetic load.藏绵羊基因组ROH热点区域内有害基因的积累不会导致遗传负荷。
BMC Genomics. 2025 Jan 22;26(1):60. doi: 10.1186/s12864-025-11207-7.
7
Metabolic-Associated Fatty Liver Disease: The Influence of Oxidative Stress, Inflammation, Mitochondrial Dysfunctions, and the Role of Polyphenols.代谢相关脂肪性肝病:氧化应激、炎症、线粒体功能障碍的影响及多酚的作用
Pharmaceuticals (Basel). 2024 Oct 10;17(10):1354. doi: 10.3390/ph17101354.
8
Targeting hepatic macrophages for non-alcoholic fatty liver disease therapy.以肝脏巨噬细胞为靶点治疗非酒精性脂肪性肝病
Front Cell Dev Biol. 2024 Sep 5;12:1444198. doi: 10.3389/fcell.2024.1444198. eCollection 2024.
9
Macrophage-Hepatocyte Circuits Mediated by Grancalcin Aggravate the Progression of Metabolic Dysfunction Associated Steatohepatitis.钙粒蛋白介导的巨噬细胞-肝细胞环路加剧代谢相关脂肪性肝炎的进展。
Adv Sci (Weinh). 2024 Nov;11(42):e2406500. doi: 10.1002/advs.202406500. Epub 2024 Sep 16.
10
DNA sensors in metabolic and cardiovascular diseases: Molecular mechanisms and therapeutic prospects.代谢性疾病和心血管疾病中的DNA传感器:分子机制与治疗前景
Immunol Rev. 2025 Jan;329(1):e13382. doi: 10.1111/imr.13382. Epub 2024 Aug 19.
细胞成熟和组织微环境对单核细胞和巨噬细胞内体 Toll 样受体表达的影响。
Int Immunol. 2020 Nov 23;32(12):785-798. doi: 10.1093/intimm/dxaa055.
4
Metabolism-Associated Molecular Patterns (MAMPs).代谢相关分子模式(MAMPs)。
Trends Endocrinol Metab. 2020 Oct;31(10):712-724. doi: 10.1016/j.tem.2020.07.001. Epub 2020 Aug 14.
5
The role of peroxisome proliferator-activated receptors (PPAR) in immune responses.过氧化物酶体增殖物激活受体 (PPAR) 在免疫应答中的作用。
Metabolism. 2021 Jan;114:154338. doi: 10.1016/j.metabol.2020.154338. Epub 2020 Aug 11.
6
Neutrophil Extracellular Traps: Signaling Properties and Disease Relevance.中性粒细胞胞外诱捕网:信号特性与疾病相关性
Mediators Inflamm. 2020 Jul 28;2020:9254087. doi: 10.1155/2020/9254087. eCollection 2020.
7
Real-World Burden of Nonalcoholic Steatohepatitis.非酒精性脂肪性肝炎的真实世界负担。
Clin Gastroenterol Hepatol. 2021 May;19(5):1020-1029.e7. doi: 10.1016/j.cgh.2020.06.064. Epub 2020 Jul 4.
8
From NAFLD to MAFLD: when pathophysiology succeeds.从非酒精性脂肪性肝病到代谢相关脂肪性肝病:病理生理学的成功转变
Nat Rev Gastroenterol Hepatol. 2020 Jul;17(7):387-388. doi: 10.1038/s41575-020-0316-6. Epub 2020 May 27.
9
Hepatocyte mitochondria-derived danger signals directly activate hepatic stellate cells and drive progression of liver fibrosis.肝细胞线粒体来源的危险信号直接激活肝星状细胞,推动肝纤维化进展。
Nat Commun. 2020 May 12;11(1):2362. doi: 10.1038/s41467-020-16092-0.
10
Mitochondrial DNA from hepatocytes induces upregulation of interleukin-33 expression of macrophages in nonalcoholic steatohepatitis.肝细胞线粒体 DNA 诱导非酒精性脂肪性肝炎中巨噬细胞白细胞介素 33 的表达上调。
Dig Liver Dis. 2020 Jun;52(6):637-643. doi: 10.1016/j.dld.2020.03.021. Epub 2020 Apr 29.